An era of biological treatment in systemic lupus erythematosus.
作者信息
He Jing, Li Zhanguo
机构信息
Department of Rheumatology & Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.
出版信息
Clin Rheumatol. 2018 Jan;37(1):1-3. doi: 10.1007/s10067-017-3933-x. Epub 2017 Dec 12.
Abstract
摘要
相似文献
1
An era of biological treatment in systemic lupus erythematosus.系统性红斑狼疮的生物治疗时代。
Clin Rheumatol. 2018 Jan;37(1):1-3. doi: 10.1007/s10067-017-3933-x. Epub 2017 Dec 12.
2
The uncertain pathway to new therapeutics for SLE.
Nat Clin Pract Rheumatol. 2009 Feb;5(2):61. doi: 10.1038/ncprheum0992.
3
Rituximab treatment in a child with rosai-dorfman disease and systemic lupus erythematosus.利妥昔单抗治疗一名患有罗萨伊-多夫曼病和系统性红斑狼疮的儿童。
J Rheumatol. 2010 Aug 1;37(8):1783-4. doi: 10.3899/jrheum.091275.
4
New therapies for systemic lupus erythematosus.系统性红斑狼疮的新疗法。
Clin Exp Immunol. 2005 May;140(2):205-12. doi: 10.1111/j.1365-2249.2005.02795.x.
5
Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.风湿病学的最新进展：治疗类风湿关节炎的生物制剂、银屑病关节炎的进展、系统性红斑狼疮中的自身抗体。
Clin Exp Dermatol. 2005 Mar;30(2):201-4. doi: 10.1111/j.1365-2230.2005.01731.x.
6
[Biological treatment of rare inflammatory rheumatic diseases].[罕见炎性风湿性疾病的生物治疗]
Ugeskr Laeger. 2008 Jun 9;170(24):2150-2.
7
Rituximab and lupus interstitial lung disease: friend or foe?利妥昔单抗与狼疮性间质性肺病：是友还是敌？
Int J Rheum Dis. 2011 Feb;14(1):e3-4. doi: 10.1111/j.1756-185X.2010.01592.x. Epub 2011 Jan 24.
8
Renal manifestations of rheumatological disorders.
J Indian Med Assoc. 2013 Aug;111(8):542-4, 552.
9
Immunologic reconstitution after rituximab in systemic lupus erythematosus: why should we care?利妥昔单抗治疗系统性红斑狼疮后的免疫重建：我们为何要关注？
J Rheumatol. 2011 Apr;38(4):587-9. doi: 10.3899/jrheum.101350.
10
Systemic lupus erythematosus: modern strategies for management: a moving target.系统性红斑狼疮：现代管理策略：一个不断变化的目标。
Best Pract Res Clin Rheumatol. 2007 Dec;21(6):971-87. doi: 10.1016/j.berh.2007.09.002.
引用本文的文献
1
What are the benefits and harms of belimumab for patients with systemic lupus erythematosus?: A Cochrane Review summary with commentary.贝利尤单抗对系统性红斑狼疮患者的益处与危害有哪些？：一篇带有评论的Cochrane系统评价总结
Int J Rheum Dis. 2021 Oct;24(10):1331-1333. doi: 10.1111/1756-185X.14214. Epub 2021 Sep 14.
2
The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.新型补体抑制剂 CRlg/FH 可改善狼疮易感 MRL/lpr 小鼠的狼疮肾炎。
BMC Nephrol. 2019 Nov 21;20(1):424. doi: 10.1186/s12882-019-1599-0.
3
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.低剂量白细胞介素 2 治疗系统性红斑狼疮的疗效和安全性：一项随机、双盲、安慰剂对照试验。
Ann Rheum Dis. 2020 Jan;79(1):141-149. doi: 10.1136/annrheumdis-2019-215396. Epub 2019 Sep 19.
本文引用的文献
1
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.在一项随机的 I 期研究中，重复给予 dapiroizumab pegol 具有良好的耐受性，并伴有全身性红斑狼疮疾病活动的几个综合指标的改善，以及全血转录组谱的变化。
Ann Rheum Dis. 2017 Nov;76(11):1837-1844. doi: 10.1136/annrheumdis-2017-211388. Epub 2017 Aug 5.
2
Antigen-specific immunotherapies in rheumatic diseases.风湿性疾病的抗原特异性免疫治疗。
Nat Rev Rheumatol. 2017 Sep;13(9):525-537. doi: 10.1038/nrrheum.2017.107. Epub 2017 Jul 13.
3
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.依鲁替尼治疗中重度活动系统性红斑狼疮的疗效和安全性：两项 III 期随机、双盲、安慰剂对照临床试验结果。
Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856.
4
Remission in systemic lupus erythematosus: durable remission is rare.系统性红斑狼疮的缓解：持久缓解罕见。
Ann Rheum Dis. 2017 Mar;76(3):547-553. doi: 10.1136/annrheumdis-2016-209489. Epub 2016 Aug 24.
5
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.低剂量白细胞介素-2 治疗可选择性调节系统性红斑狼疮患者的 CD4(+) T 细胞亚群。
Nat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8.
6
Systemic lupus erythematosus.系统性红斑狼疮。
Nat Rev Dis Primers. 2016 Jun 16;2:16039. doi: 10.1038/nrdp.2016.39.
7
Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study.脐带间充质干细胞移植治疗系统性红斑狼疮的长期安全性：一项 6 年随访研究。
Clin Exp Med. 2017 Aug;17(3):333-340. doi: 10.1007/s10238-016-0427-0. Epub 2016 Jun 7.
8
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.西法莫单抗，一种抗干扰素-α单克隆抗体，用于中重度系统性红斑狼疮：一项随机、双盲、安慰剂对照研究。
Ann Rheum Dis. 2016 Nov;75(11):1909-1916. doi: 10.1136/annrheumdis-2015-208562. Epub 2016 Mar 23.
9
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody.抗干扰素-α受体1抗体阿尼鲁单抗拮抗活性的分子基础。
MAbs. 2015;7(2):428-39. doi: 10.1080/19420862.2015.1007810.
10
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.靶向治疗系统性红斑狼疮：国际工作组的建议。
Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16.
Zotero 插件